ZUMA-2

 Titel: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)(ZUMA-2)

9 jan 2023.  studie is gesloten voor inclusie. 

Cohort 3 is gesloten per 21 april 2023

• r/r MCL who have been treated with up to 5 prior regimens but have not received prior therapy with a BTKi.
• Prior therapy must have included anthracycline or bendamustine-containing chemotherapy and anti-CD20 monoclonal antibody therapy.

• Protocol  (k2)
• Patienteninformatie (k2)
• Patienteninformatie zwangere partner (k2)
• Safety information
• Flowchart CRS en neurotoxiciteit (k2)
• Investigators Brochure (k2)
• Tocilizumab risico informatie
• Toxicititeit management tool

Studiemedicatie:

BEACONprotocol beschikbaar:

Verpleegkundige documenten:

Principal Investigator AMC: Marie Jose Kersten

Studie coordinator: Rob Liu

Aanmelden patienten via trialbureau hematologie (sein 29255, hemat.trial@amc.nl)